Breast MRI Fibroglandular Volume and Parenchymal Enhancement in @entity5345 and XXXX Mutation Carriers Before and Immediately After Risk-Reducing Salpingo-Oophorectomy.

@entity1 @entity0 @entity146 @entity5345 @entity2674
UNASSIGNED: OBJECTIVE. The purpose of this article is to assess the difference in fibroglandular volume and background parenchymal enhancement in @entity5345 and @entity2674 mutation carriers on contrast-enhanced breast MRI (CE-MRI) performed before and immediately after @entity146 ( @entity146 ). MATERIALS AND METHODS. We retrospectively compared fibroglandular volume and background parenchymal enhancement in 55 female @entity5345 and @entity2674 mutation carriers before and after @entity146 using standard BI-RADS categories and a paired Wilcoxon and Mann-Whitney U test. A two-sample Wilcoxon test was performed to compare fibroglandular volume and background parenchymal enhancement in @entity1 with and without subsequent @entity0 diagnosis on follow-up. RESULTS. The median time to post- @entity146 CE-MRI was 8 months (range, 1-40 months). There was no difference in fibroglandular volume before and after @entity146 (p = 0.65). The mean background parenchymal enhancement was 2.5 (range, 1-4) before and 1.5 (range, 1-4) after @entity146 (overall range, -2.5 to 1.5; p = 0.0001). @entity0 was detected in nine @entity1 at a median time of 4.8 years (range, 1.8-13.3 years) after @entity146 . For @entity1 who received a diagnosis of @entity0 after @entity146 compared with those who did not, mean background parenchymal enhancement before @entity146 was 3 (range, 2-4) versus 2.5 (range, 1-4; p = 0.001), and mean background parenchymal enhancement after @entity146 was 2.5 (range, 1.5-4) versus 1.5 (range 2-4; p = 0.0018). There was no difference in fibroglandular volume before and after @entity146 . CONCLUSION. In @entity5345 and @entity2674 mutation carriers, we observed a significant reduction in background parenchymal enhancement on the first CE-MRI after @entity146 and no significant change in fibroglandular volume. Higher background parenchymal enhancement before and after @entity146 was observed in @entity1 who subsequently received a diagnosis of @entity0 . This suggests that background parenchymal enhancement, rather than fibro-glandular volume, may be a more sensitive imaging biomarker of @entity0 risk.
